Intellia Therapeutics (NTLA) Stock Price, News & Analysis

+0.78 (+3.57%)
(As of 10:40 AM ET)
Today's Range
50-Day Range
52-Week Range
183,263 shs
Average Volume
1.49 million shs
Market Capitalization
$2.18 billion
P/E Ratio
Dividend Yield
Price Target

Intellia Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.69 Rating Score
206.9% Upside
$67.00 Price Target
Short Interest
15.38% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.87mentions of Intellia Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$75,778 Sold Last Quarter
Proj. Earnings Growth
From ($5.58) to ($5.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.79 out of 5 stars

Medical Sector

209th out of 910 stocks

Diagnostic Substances Industry

4th out of 11 stocks

NTLA stock logo

About Intellia Therapeutics Stock (NASDAQ:NTLA)

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Stock Price History

NTLA Stock News Headlines

A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Smart Money Is Betting Big In NTLA Options
Here’s how to start a “Weekend Side Hustle” from your sofa
Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.
Intellia Therapeutics Is On The Move
Intellia Therapeutics just downgraded at Goldman Sachs, here's why
Q4 2023 Intellia Therapeutics Inc Earnings Call
See More Headlines
Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
13 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$36.28 million
Book Value
$11.73 per share


Free Float
Market Cap
$2.11 billion
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. John M. Leonard M.D. (Age 67)
    President, CEO & Director
    Comp: $1.06M
  • Mr. Glenn G. Goddard CPAMr. Glenn G. Goddard CPA (Age 53)
    Executive VP, CFO & Treasurer
    Comp: $630.91k
  • Dr. Laura Sepp-Lorenzino Ph.D. (Age 63)
    Executive VP & Chief Scientific Officer
    Comp: $670.58k
  • Mr. James E. Basta Esq. (Age 58)
    J.D., Executive VP, General Counsel & Corporate Secretary
    Comp: $616.15k
  • Dr. David Lebwohl M.D. (Age 69)
    Executive VP & Chief Medical Officer
    Comp: $671.42k
  • Mr. Derek Hicks (Age 50)
    Executive VP & Chief Business Officer
    Comp: $823.42k
  • Mr. Nessan Bermingham Ph.D. (Age 51)
    Founder & Member of Scientific Advisor Board
    Comp: $1.38M
  • Dr. Rachel E. Haurwitz Ph.D. (Age 38)
  • Dr. Andrew May Ph.D.
    Founder and Member of Scientific Advisor Board
  • Dr. Jennifer A. Doudna Ph.D. (Age 60)
    Founder & Member of Scientific Advisor Board

NTLA Stock Analysis - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NTLA shares.
View NTLA analyst ratings
or view top-rated stocks.

What is Intellia Therapeutics' stock price target for 2024?

13 Wall Street research analysts have issued 12-month price objectives for Intellia Therapeutics' shares. Their NTLA share price targets range from $29.00 to $107.00. On average, they anticipate the company's stock price to reach $67.00 in the next year. This suggests a possible upside of 206.9% from the stock's current price.
View analysts price targets for NTLA
or view top-rated stocks among Wall Street analysts.

How have NTLA shares performed in 2024?

Intellia Therapeutics' stock was trading at $30.49 at the beginning of 2024. Since then, NTLA shares have decreased by 28.4% and is now trading at $21.83.
View the best growth stocks for 2024 here

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NTLA earnings forecast

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its quarterly earnings results on Thursday, February, 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. The business earned ($1.92) million during the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 43.91% and a negative net margin of 893.34%. During the same period in the prior year, the company earned ($1.40) earnings per share.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

Intellia Therapeutics (NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (3.52%), Los Angeles Capital Management LLC (0.02%), Allspring Global Investments Holdings LLC (0.01%), SteelPeak Wealth LLC (0.01%) and Green Alpha Advisors LLC (0.01%). Insiders that own company stock include David Lebwohl, Eliana Clark, Glenn Goddard, James Basta, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Laura Sepp-Lorenzino and Muna Bhanji.
View institutional ownership trends

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTLA) was last updated on 4/23/2024 by Staff

From Our Partners